Source Precision Medicine, Inc. d/b/a Source MDx Announces 16 Molecular Diagnostic Development Programs Will Be Offered for Sale on April 29, 2011

WELLESLEY HILLS, Massachusetts, March 29, 2011 - Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the Benefit of
Creditors of Source Precision Medicine, Inc., d/b/a Source MDx ("Source MDx")
announced that 16 molecular diagnostic development programs will be offered
for sale on April 29, 2011.

These molecular diagnostic programs are blood-based, not tissue-based.
Eight programs cover the following cancers: prostate, lung, breast, cervical,
ovarian, colon, bladder and melanoma. In addition, two programs cover
infectious diseases: sepsis and hepatitis C infection; three programs cover
autoimmune diseases: rheumatoid arthritis, multiple sclerosis, lupus,
osteoarthritis and ocular and one covers transplant rejection.

Persons interested in bidding must sign a Confidentiality Disclosure
Agreement ("CDA") obtained from Finn's office - jffinnjr@finnwarnkegayton.com
or +1-781-237-8840. They will then receive a bid package.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm Finn,
Warnke & Gayton LLP of Wellesley Hills, Massachusetts
(www.finnwarnkegayton.com). He works primarily in the area of
management consulting for distressed enterprises, bankruptcy accounting and
related matters, such as Assignment for the Benefit of Creditors and
Liquidating Agent for corporations. He has been involved in a number of loan
workouts and bankruptcy cases for thirty-six (36) years. His most recent
Assignments for the Benefit of Creditors in the biotech filed include
Spherics, Inc., ActivBiotics, Inc., Prospect Therapeutics, Inc. and Epix
Pharmaceuticals, Inc.

Joseph F. Finn, Jr., C.P.A., +1-781-237-8840, jffinnjr at finnwarnkegayton.com